Compare Sibanye Stillwater Ltd (SBSW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs Spyre Therapeutics Inc. Common Stock — how do they compare? Sibanye Stillwater Ltd trades at $9.63 (market cap $6.99B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Sibanye Stillwater Ltd and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SBSW | SYRE | |
|---|---|---|
Market Cap | $6.99B | $7.52B |
Volume | 3,905,859 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $108.92 |
52-Week Low | $8.00 | $22.18 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $7.89B | $6.52B |
Dividend Yield | 8.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $9.42, down 4.75% on the day, amid a bearish technical signal. The company reported a net loss of $5.17 billion in 2025 despite revenue of $129.68 billion, though profitability is projected to improve significantly in 2026. Analyst consensus is a Moderate Buy with a $14.25 price target. Recent news highlights strong first-half 2026 results, including 54% revenue growth and a surge in operating cash flow, signaling a potential turnaround.
The outlook for SBSW hinges on executing its growth roadmap and capital discipline. Investment opportunities include attractive valuation multiples and projected earnings recovery, but risks persist from commodity price volatility, high debt levels, and operational challenges in South African mining. The stock offers value if management delivers on its 2027-2028 targets.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
